's step-down subsidiary, Acrotech Biopharma, announced that the US FDA has approved ADQUEY (difamilast 1%) ointment for mild-to-moderate atopic dermatitis in adults and children aged two years and older. ADQUEY is a non-steroidal, topical phosphodiesterase 4 (PDE4) inhibitor, offering a new treatment option for millions of Americans with atopic dermatitis. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.